STOCK TITAN
  1. Home
  2. News
  3. AKYA

Akoya BioSciences, Inc. - AKYA STOCK NEWS

Welcome to our dedicated news page for Akoya BioSciences (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya BioSciences .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Akoya BioSciences 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Akoya BioSciences 's position in the market.

News
Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Akoya Biosciences, Inc. (Nasdaq: AKYA) will be participating in the 42nd Annual J.P. Morgan Healthcare Conference. CEO Brian McKelligon is scheduled to present on January 10th, 2024. A live and archived webcast of the event will be available on the Akoya website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
conferences
-
News
Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
Rhea-AI Summary
Akoya Biosciences, Inc. (Nasdaq: AKYA) announced Q3 2023 revenue of $25.2 million, marking a 34% year-over-year growth. The company also reiterated its FY 2023 revenue guidance range of $95-98 million. The financial results show strong performance, with total revenue, product revenue, and gross profit all increasing significantly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.9%
Tags
none
-
News
Akoya to Participate at Three Upcoming Investor Conferences
Rhea-AI Summary
Akoya Biosciences, Inc. (Nasdaq: AKYA) will be participating in three upcoming investor conferences: Stephens Annual Investment Conference, Canaccord Genuity 2023 MedTech, Diagnostics and Digital Health & Services Forum, and Piper Sandler 35th Annual Healthcare Conference. The fireside chats will cover various topics related to the company's spatial biology solutions. The events will be webcasted live and archived on the Akoya website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.92%
Tags
conferences
News
Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023
Rhea-AI Summary
Akoya Biosciences Inc. will showcase its latest Spatial Biology 2.0 solutions and ultrahigh-plex spatial phenotyping data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The company will highlight its new PhenoCycler-Fusion 2.0 and PhenoImager HT 2.0 platforms, which offer advancements in speed and scale for spatial biology research. Akoya's global network of CROs will also be exhibiting at SITC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
none
-
News
Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures
Rhea-AI Summary
Akoya Biosciences and The University of Queensland's Frazer Institute have mapped the spatial proteome of head and neck squamous cell carcinoma (HNSCC) using ultrahigh-plex spatial phenotyping. The study reveals the heterogeneity of head and neck cancers and provides insights into the mechanistic basis of variable clinical responses. The research highlights the enrichment of specialized immune cell subsets and metabolic and stress signatures within specific spatial domains in the tumor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
none
-
News
Akoya to Report Third Quarter 2023 Financial Results on November 8th, 2023
Rhea-AI Summary
Akoya Biosciences to release Q3 2023 financial results on November 8th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.1%
Tags
conferences earnings
News
Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms
Rhea-AI Summary
Akoya Biosciences highlights industry-leading scale and speed in spatial biology workflows with PhenoCycler-Fusion 2.0 and PhenoImager HT 2.0 upgrades
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
none
-
News
Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
none
-
News
Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
none
News
Akoya to Participate at Three Upcoming Investor Conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
conferences
Stock AKYA logo
Akoya BioSciences, Inc.

Nasdaq:AKYA

AKYA Rankings

#3812 Ranked by Market Cap
#5269 Ranked by Stock Gains
N/A Ranked by Dividends

AKYA Stock Data

190.61M
17.38M
12.87%
72.24%
2.01%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States of America
MARLBOROUGH

About AKYA

akoya biosciences is developing a novel high-parameter tissue analysis platform, at an order of magnitude beyond what is currently possible. our codex (tm) (co-detection by indexing) system enables deep proteomic profiling.​..all on your existing microscope​. if you are a scientist or software engineer interested in revolutionizing the science of imaging, then akoya is the place for you. contact is at info@akoyabio.com.